Please login to the form below

Not currently logged in
Email:
Password:

Brilinta outperforms Plavix in trial

Top-line results for AstraZeneca's pipeline drug Brilinta have shown that it outperforms in a head-to-head with competing medication, Plavix

Top-line results for AstraZeneca's pipeline drug Brilinta have shown that it outperforms in a head-to-head with competing medication, Plavix from Bristol-Myers Squibb and sanofi-aventis.

Both products are used in the prevention of cardiovascular events in patients with acute coronary syndromes (ACS) and the results raise AstraZeneca's hopes for a pipeline product that analysts see as a potential multibillion-dollar-a-year seller. Analysts at the French brokerage Natixis estimate potential peak sales for Brilinta to treat ACS at $600m.

The new medicine is seen as a chance for AstraZeneca to prove its ability to get major new drugs to market following a drought of new product launches in recent years.

The PLATO (A Study of Platelet Inhibition and Patient Outcomes) study involved 18,624 ACS patients in 43 countries and was led by Professor Lars Wallentin at Sweden's Uppsala Clinical Research Center and co-chaired by Professor Robert Harrington, Duke Clinical Research Institute, in the US. The head-to-head study of the two drugs is one of the largest comparative trials ever undertaken before approval.

AstraZeneca said it plans to submit Brilinta for regulatory approval in the fourth quarter. The company intends to submit the data to a peer-reviewed medical journal and present at the European Society of Cardiology annual meeting in August.

The trial also demonstrated that the overall safety profile for Brilinta was in line with the safety data observed in the phase II studies.

About one in three ACS patients die, have a recurrent heart attack (also known as myocardial infarction), or are readmitted to hospital within six months of their first cardiovascular event occurrence.

11th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics